Neurologists from multiple clinics shared data at AAIC on the Alzheimer's drug's use, shedding light on its safety and ...

The firm will retain rights to its preclinical assets including two T-cell receptor T-cell therapies and its allogenic program.

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

The FDA investigated the death of a boy in Brazil on Elevidys and concluded it was unrelated to the treatment.

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline growth drivers.